For the Inventor, By the Inventor

Enter assignee name

Lausanne, Switzerland

Debiopharm S.a.

USPTO Granted Patents = 28

% Expired Patents = 21.4

CIPO Patents = 1

EPO Patents = 6

Trademarks = 3

Forward Citations = 744

Loading Chart...

Loading Chart...

49 inventors (with patents filed for the assignee):

Piero Orsolini (7 out of 17 patents)

Rolland-Yves Mauvernay (6 out of 10 patents)

Houssam Ibrahim (5 out of 5 patents)

4. Manfred Mutter (4 out of 5 patents)

5. Roland M Wenger (4 out of 17 patents)

6. Romano Deghenghi (3 out of 4 patents)

7. Saumitra Sengupta (2 out of 12 patents)

8. Grégoire Vuagniaux (2 out of 8 patents)

9. Maximilien Murone (2 out of 8 patents)

10. Andrès Mc Allister (2 out of 2 patents)

11. Shankar Jayaram Shetty (2 out of 2 patents)

12. Henri Pourrat (2 out of 2 patents)

13. Christine Deuschel (2 out of 2 patents)

14. Alain Poncin (2 out of 2 patents)

15. Anne Bokman (2 out of 2 patents)

Core Competencies:

Dual Inhibitors

c-SRC

JAK

HCV Drug Resistance

Oxaliplatinum

Cyclic Peptides

Biologically Active Derivatives

Pharmaceutical Compositions

Microencapsulation

Polypeptides

Cinchonine

Therapeutic Agents

28 patents: Sort by Forward Citations

1. 8962637 - Bicyclic compounds and their uses as dual c-SRC/JAK inhibitors (2015-02-24),

2. 8911934 - Near full-genome assay of HCV drug resistance (2014-12-16),

3. 8450281 - Non-immunosuppressive cyclosporin for treatment of Ullrich congenital muscular dystrophy (2013-05-28),

4. 8440679 - Bicyclic compounds and their uses as dual c-SRC / JAK inhibitors (2013-05-14),

5. 8211940 - Oxaliplatin active substance with a very low content of oxalic acid (2012-07-03),

6. RE40987 - Cyclosporin with improved activity profile (2009-11-16),

7. 7070796 - Pharmaceutically stable oxaliplatinum preparation for parenteral administration (2006-07-04),

8. 7012072 - Pharmaceutical oxaliplatinum preparation for parenteral administration and method for obtaining same (2006-03-14),

9. 6995139 - Cyclic undecapeptide pro-drugs and uses thereof (2006-02-07),

10. 6989438 - Process for the purification of EPI-HNE proteins (2006-01-24),

11. 6927208 - Cyclosporin with improved activity profile (2005-08-09),

12. 6866857 - Oxalipatinum preparation packaging (2005-03-15),

13. 6814982 - Suspension of an EPI-HNE protein, process of preparation thereof, dry powder aerosol derived therefrom, pharmaceutical compositions containing said suspension or aerosol, and their uses (2004-11-09),

14. 6790935 - Cyclosporin derivatives and method for the production of said derivatives (2004-09-14),

15. 6528524 - Pharmaceutical compositions containing cinchonine dichlorhydrate (2003-03-04),

Company Overview

Debiopharm S.A., based in Lausanne, Switzerland, is a biopharmaceutical company focused on the development of innovative therapies for oncology and infectious diseases. The organization specializes in drug development, particularly in the areas of targeted therapies and personalized medicine. With a commitment to advancing healthcare, Debiopharm collaborates with various partners to enhance treatment options and improve patient outcomes globally, leveraging cutting-edge research and technology in the pharmaceutical sector.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

28 Patents

#11 in Lausanne

#475 in Switzerland

#23,285 in the World

Lausanne, Switzerland

Debiopharm S.a.

Forward Citations = 744

49 inventors:

Piero Orsolini (7 out of 17 patents)

Rolland-Yves Mauvernay (6 out of 10 patents)

Houssam Ibrahim (5 out of 5 patents)

4. Manfred Mutter (4 out of 5 patents)

5. Roland M Wenger (4 out of 17 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Debiopharm S.a.. Retrieved from https://idiyas.com/company/debiopharm-s-a

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…